A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome
Joan Bladé,Pieter Sonneveld,Jesús F. San Miguel,Heather J. Sutherland,Roman Hájek,Arnon Nagler,Andrew Spencer,Tadeusz Robak,Keith C. Lantz,Sen H. Zhuang,Jean Luc Harousseau,Robert Z. Orlowski +11 more
TL;DR: Treatment of relapsed/refractory myeloma with the combination of PLD plus bortezomib provides better outcomes over bortzomib alone, even in the presence of high-risk prognostic factors.
Journal ArticleDOI
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.
Avichai Shimoni,Myriam Labopin,Bipin N. Savani,Rose Marie Hamladji,Dietrich W. Beelen,Ghulam J. Mufti,Gérard Socié,Jeremy Delage,Didier Blaise,Patrice Chevallier,Edouard Forcade,Eric Deconinck,Mohamad Mohty,Arnon Nagler +13 more
TL;DR: Treosulfan-based conditioning is more similar to myeloablative than to reduced-intensity conditioning but can be administered safely in older patients, with lower rates of graft-versus-host disease and possibly better outcomes in patients with active leukemia.
Journal ArticleDOI
Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis
Jonathan Canaani,Eric Beohou,M. Labopin,A. Ghavamzadeh,Dietrich W. Beelen,Rose-Marie Hamladji,Dietger Niederwieser,Liisa Volin,Miroslaw Markiewicz,Renate Arnold,Ghulam J. Mufti,G. Ehninger,Gérard Socié,Nicolaus Kröger,M. Mohty,Arnon Nagler +15 more
TL;DR: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo‐SCT) have significantly improved in recent years.
Journal ArticleDOI
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
Ali Bazarbachi,Christoph Schmid,Myriam Labopin,Dietrich W. Beelen,Igor Wolfgang Blau,Victoria Potter,Riitta Niittyvuopio,Gérard Socié,Didier Blaise,Jaime Sanz,Fabio Ciceri,Iman Abou Dalle,Alexandros Spyridonidis,Gesine Bug,Jordi Esteve,Bipin N. Savani,Arnon Nagler,Mohamad Mohty +17 more
TL;DR: Outcome after posttransplant relapse among younger patients has improved significantly in recent years, likely reflecting, among other factors, the efficacy of posttrans transplant salvage including second allo-HCT.
Journal ArticleDOI
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?
Tara M. Robinson,Ephraim J. Fuchs,Mei-Jie Zhang,Andrew St. Martin,Myriam Labopin,Daniel A. Keesler,Didier Blaise,Asad Bashey,Jean-Henri Bourhis,Fabio Ciceri,Stefan O. Ciurea,Steven M. Devine,Mohamad Mohty,Shannon R. McCurdy,Noel Milpied,Ian McNiece,Vanderson Rocha,Rizwan Romee,Gérard Socié,Ibrahim Yakoub-Agha,Robert J. Soiffer,Mary Eapen,Arnon Nagler +22 more
TL;DR: Data demonstrate a superior outcome in older recipients when using an HLA-matched sibling instead of offspring, although there were differences in transplant platforms (GVHD prophylaxis and graft type) between the 2 groups.